Clinical trials: Cyclophosphamide
Breast Cancer
Study of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction
The main clinical goal of NAC is to down-stage the primary tumor for BCS,yet BCS after NAC has been associated with significantly higher ipsilateral breast tumor recurrences.The accuracy of breast tumor excision in BCS can…
- Trial name
- BCSMANC (NCT01917578)
- Testing
- Ultrasound, CNB, BCS, Modified Radical Mastectomy
- Where
- China
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Shandong Cancer Hospital and Institute
Peripheral T-cell Lymphomas, Lymphoproliferative Disorders
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
Background: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause.
- Conditions
- Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases
- Trial name
- NCT03922724
- Testing
- ATL-RIC, mRIC, allo HCT
- Where
- 2 sites in United States
- Volunteers
- 118 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
DOCK8 Deficiency
Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency
Background: -DOCK8 deficiency is a genetic disorder that affects the immune system and can lead to severe recurrent infections and possible death from infections or certain types of cancers, including blood cancers.
- Trial name
- NCT01176006
- Testing
- Reduced-intensity hematopoietic stem cell, Fludarabine(Fludara, Berlex Laboratories), Cyclophosphamide(CTX, Cytoxan)
- Where
- United States
- Volunteers
- 76 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies
Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft
Reduced intensity conditioning (RIC) has emerged and been increasingly adopted as a modality to allow preparative conditioning pre transplant to be tolerated by older adults or those patients that are otherwise unfit for…
- Conditions
- Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT05088356
- Testing
- Purified regulatory T-cells (Treg) plus CD34+ HSPC, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Stanford University
Lymphoma, Leukemia
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
Background: Patients with cancers of the blood and immune system often benefit from transplants of stem cells from a genetically well-matched sibling.
- Conditions
- Lymphoma, Leukemia, Myeloproliferative Disorders, Multiple Myleoma
- Trial name
- NCT00074490
- Testing
- Rituximab, Fludarabine, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 442 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Metastatic Breast Cancer, Tumor
Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor
At a median follow-up of 33 months, the combination of anastrozole and NOLVADEX (tamoxifen citrate) did not demonstrate any efficacy benefit when compared to NOLVADEX (tamoxifen citrate) therapy given alone in all patients as…
- Conditions
- Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain
- Trial name
- NASBP-B-09 (NCT06154590)
- Testing
- Method(s)1 Attribution, Method(s)2 Attribution,
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- DR. DIANE CHISESI NFS. MD. PHD.
Genital Wart
Low Dose Cyclophosphamide Treats Genital Warts
Condylomata acuminata (CA) caused by human papillomavirus (HPV) is a common sexually transmitted disease with half a million new cases diagnosed in the United States per year. Recurrence is a major challenge for CA treatment.
- Trial name
- NCT00999986
- Testing
- cyclophosphamide
- Where
- China
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Huazhong University of Science and Technology
Primary Myelofibrosis, Secondary Myelofibrosis
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
This early phase I trial studies the side effects of combination chemotherapy, total body irradiation, and donor blood stem cell transplant in treating patients with primary or secondary myelofibrosis.
- Trial name
- NCT03426969
- Testing
- Cyclophosphamide, Filgrastim, Fludarabine Phosphate
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Lupus Nephritis
Anti-alpha-actinin Antibodies and Lupus Nephritis Activity
Lupus nephritis (LN) develops in 30-60% of systemic lupus erythematosus (SLE) patients and remains a leading cause of morbidity, with 10-30% progressing to end-stage renal disease within 15 years.
- Trial name
- NCT07505576
- Testing
- renal biopsy, serum anti-alpha-actinin antibodies, CBC, serum creatinine and urea, estimated GFR, ESR, CRP, urine analysis, ANA, anti dsDNA, C3 & C4, serum albumin, 24-hrs urinary protein, and U. ACR
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- Assiut University
Large B-cell Lymphoma, Diffuse Large B-cell Lymphoma
Chimeric Antigen Receptor (CAR) T Cell Therapy With YESCARTA in the Outpatient Setting
We hope to demonstrate that YESCARTA can be safely administered in the outpatient setting if we closely monitor subjects with physical exams, wearable devices, and telemedicine visits and only admit those who meet specified…
- Trial name
- NCT05108805
- Testing
- Telemedicine Visit, Vital sign measurements, Out-Patient Clinic Visit
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Vanderbilt-Ingram Cancer Center
Carcinoma Breast Stage IV
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT02183805
- Testing
- Abraxane,Cyclophosphamide,Carboplatin
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
This phase I trial tests the safety, side effects and best dose of NEXI-001 when given with decitabine and lymphodepleting chemotherapy in treating patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that…
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
- Trial name
- NCT06572631
- Testing
- Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001, Biospecimen Collection, Bone Marrow Aspiration
- Volunteers
- healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia
QUILT-3.033: Haplo NK With SQ ALT-803 for Adults With Relapsed or Refractory AML
This is a multi-institutional Simon's optimal two-stage phase II trial of CD3/CD19 depleted, ALT-803 activated, haploidentical donor NK cells and subcutaneous ALT-803 given after lymphodepleting chemotherapy (CY/FLU) for the…
- Trial name
- NCT03050216
- Testing
- ALT-803
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Masonic Cancer Center, University of Minnesota
Lymphoma, Large B-Cell, Diffuse, Leukemia, Lymphocytic, Chronic, B-Cell
a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell Malignancies
The main purpose of this study is to explore the sequential therapeutic effect and evaluate the safety of anti-CD19 or anti-CD20 CAR-T cells briging HSCT in the treatment of relapse/refractory B cell malignancies.
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma，Malignant
- Trial name
- NCT02846584
- Testing
- CD19 or CD20 CAR T cells briging HSCT
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Southwest Hospital, China
Systemic Sclerosis
RIC alloBMT With Post-transplant Cyclophosphamide for Refractory Systemic Sclerosis
This is a Phase I, single arm, open label, single center pilot study to assess a reduced-intensity conditioning regimen, bone marrow transplantation with high dose cyclophosphamide (PTCy) in recipients with refractory systemic…
- Trial name
- NCT05298358
- Testing
- RIC alloBMT w PTCy in refractory SSc
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative
Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation
Background: Blood stem cells in the bone marrow make all the cells to normally defend a body against disease. Allogeneic blood or marrow transplant is when these stem cells are transferred from one person to another.
- Conditions
- Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Primary T-cell Immunodeficiency Disorders, Immune System Diseases
- Trial name
- NCT03663933
- Testing
- e-ATG, Immunosuppression Only Conditioning, Reduced Intensity Conditioning
- Where
- 2 sites in United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
T-Cell Dysfunction, Chemotherapy Effect
Studying the Senescent T Cell Features and Its Relationship with the Chemotherapy Efficacy in Young TNBC
The goal of this observational study is to learn about the features of senescent T lymphocytes induced by chemotherapy and its relationship with the efficacy of neoadjuvant chemotherapy in young triple-negative breast cancer…
- Conditions
- T-Cell Dysfunction, Chemotherapy Effect, Adverse Events
- Trial name
- STFREiYTNBC (NCT06684054)
- Testing
- docetaxel, anthracycline, cyclophosphamide
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Soft Tissue Sarcoma, Non Metastatic Disease
A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall
SSG XX is a phase II trial for high-risk soft tissue sarcomas (STS) of the extremities and trunk wall. Prognostic factors (histopathological markers) are used to identify high-risk tumors.
- Trial name
- SSGXX (NCT00790244)
- Testing
- doxorubicin , ifosfamide, doxorubicin, ifosfamide
- Where
- 2 sites in Sweden
- Volunteers
- 188 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Focal Segmental Glomerulosclerosis
Permeability Factor in Focal Segmental Glomerulosclerosis
Focal segmental glomerulosclerosis (FSGS) is a renal syndrome characterized by proteinuria (usually nephrotic range), limited response to conventional therapy, and a poor renal prognosis, with progression to end stage renal…
- Trial name
- NCT00007475
- Testing
- Plasma exchange, Cyclophosphamide
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Aplastic Anemia, Leukemia
Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine
This is a genetic disease (transmitted through the parents' genes) called Fanconi Anemia. Because of that genetic disease, the bone marrow has changed and now has failed, or has given rise to a preleukemia called myelodysplastic…
- Conditions
- Aplastic Anemia, Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00987480
- Testing
- Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine., CliniMACS device
- Where
- 6 sites in United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center